Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report Article Swipe
Hirokazu Iso
,
Akihiko Miyanaga
,
Naohiro Kadoma
,
Kaoruko Shinbu
,
Takehiro Tozuka
,
Akari Murata
,
Shunichi Nishima
,
Yozo Sato
,
Shinji Nakamichi
,
Masaru Matsumoto
,
Rintaro Noro
,
Yasuhiro Terasaki
,
Kaoru Kubota
,
Masahiro Seike
·
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.2147/ott.s404035
YOU?
·
· 2023
· Open Access
·
· DOI: https://doi.org/10.2147/ott.s404035
Anaplastic lymphoma kinase-positive (ALK-positive) lung adenocarcinoma with multiple liver metastases accounts for a relatively small number of cases of non-small cell lung cancer. Several ALK-tyrosine kinase inhibitors (ALK-TKIs) are available for the treatment of lung cancer. However, there is limited evidence on the treatment of multiple liver metastases in patients with lung cancer that are refractory to ALK-TKIs. We report the case of a 42-year-old male patient with ALK-positive lung adenocarcinoma who experienced rapid progression to multiple liver metastases while receiving treatment with alectinib. Biopsy of the liver metastases revealed echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK) fusion and tumor protein p53 (TP53) mutation; notably, ALK secondary mutations were not detected. Despite the sequential administration of third-generation ALK-TKIs, the liver metastases did not respond, the serum levels of total bilirubin and biliary enzymes continued to increase, and the patient's general appearance worsened. Finally, the patient exhibited a remarkable clinical response to treatment with a combination of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP). ABCP is one of the optimal options for ALK-positive lung cancer with liver metastasis that is refractory to ALK-TKIs therapy.
Related Topics
Concepts
Medicine
Crizotinib
Anaplastic lymphoma kinase
Alectinib
Bevacizumab
Lung cancer
Carboplatin
Atezolizumab
Adenocarcinoma
Cancer research
Metastasis
Internal medicine
Oncology
Cancer
Chemotherapy
Nivolumab
Immunotherapy
Malignant pleural effusion
Cisplatin
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.2147/ott.s404035
- https://www.dovepress.com/getfile.php?fileID=90671
- OA Status
- gold
- Cited By
- 5
- References
- 25
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4381803477
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4381803477Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.2147/ott.s404035Digital Object Identifier
- Title
-
Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case ReportWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2023Year of publication
- Publication date
-
2023-06-01Full publication date if available
- Authors
-
Hirokazu Iso, Akihiko Miyanaga, Naohiro Kadoma, Kaoruko Shinbu, Takehiro Tozuka, Akari Murata, Shunichi Nishima, Yozo Sato, Shinji Nakamichi, Masaru Matsumoto, Rintaro Noro, Yasuhiro Terasaki, Kaoru Kubota, Masahiro SeikeList of authors in order
- Landing page
-
https://doi.org/10.2147/ott.s404035Publisher landing page
- PDF URL
-
https://www.dovepress.com/getfile.php?fileID=90671Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.dovepress.com/getfile.php?fileID=90671Direct OA link when available
- Concepts
-
Medicine, Crizotinib, Anaplastic lymphoma kinase, Alectinib, Bevacizumab, Lung cancer, Carboplatin, Atezolizumab, Adenocarcinoma, Cancer research, Metastasis, Internal medicine, Oncology, Cancer, Chemotherapy, Nivolumab, Immunotherapy, Malignant pleural effusion, CisplatinTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 2, 2024: 3Per-year citation counts (last 5 years)
- References (count)
-
25Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4381803477 |
|---|---|
| doi | https://doi.org/10.2147/ott.s404035 |
| ids.doi | https://doi.org/10.2147/ott.s404035 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/37384219 |
| ids.openalex | https://openalex.org/W4381803477 |
| fwci | 1.68687493 |
| type | article |
| title | Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report |
| biblio.issue | |
| biblio.volume | Volume 16 |
| biblio.last_page | 470 |
| biblio.first_page | 465 |
| topics[0].id | https://openalex.org/T10417 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9998999834060669 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2740 |
| topics[0].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[0].display_name | Lung Cancer Treatments and Mutations |
| topics[1].id | https://openalex.org/T12334 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9973000288009644 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Lung Cancer Research Studies |
| topics[2].id | https://openalex.org/T11287 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.996399998664856 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1306 |
| topics[2].subfield.display_name | Cancer Research |
| topics[2].display_name | Cancer Genomics and Diagnostics |
| is_xpac | False |
| apc_list.value | 2836 |
| apc_list.currency | USD |
| apc_list.value_usd | 2836 |
| apc_paid.value | 2836 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2836 |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8374984264373779 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2779422266 |
| concepts[1].level | 4 |
| concepts[1].score | 0.8286832571029663 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q5186964 |
| concepts[1].display_name | Crizotinib |
| concepts[2].id | https://openalex.org/C117643217 |
| concepts[2].level | 4 |
| concepts[2].score | 0.7643359899520874 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q17824987 |
| concepts[2].display_name | Anaplastic lymphoma kinase |
| concepts[3].id | https://openalex.org/C2779220645 |
| concepts[3].level | 5 |
| concepts[3].score | 0.702530026435852 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q21099132 |
| concepts[3].display_name | Alectinib |
| concepts[4].id | https://openalex.org/C2777802072 |
| concepts[4].level | 3 |
| concepts[4].score | 0.6311084032058716 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q413299 |
| concepts[4].display_name | Bevacizumab |
| concepts[5].id | https://openalex.org/C2776256026 |
| concepts[5].level | 2 |
| concepts[5].score | 0.6037223935127258 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q47912 |
| concepts[5].display_name | Lung cancer |
| concepts[6].id | https://openalex.org/C2781451048 |
| concepts[6].level | 4 |
| concepts[6].score | 0.6015071272850037 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q415588 |
| concepts[6].display_name | Carboplatin |
| concepts[7].id | https://openalex.org/C2775949291 |
| concepts[7].level | 5 |
| concepts[7].score | 0.5846185684204102 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q20707748 |
| concepts[7].display_name | Atezolizumab |
| concepts[8].id | https://openalex.org/C2781182431 |
| concepts[8].level | 3 |
| concepts[8].score | 0.5373453497886658 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q356033 |
| concepts[8].display_name | Adenocarcinoma |
| concepts[9].id | https://openalex.org/C502942594 |
| concepts[9].level | 1 |
| concepts[9].score | 0.49228349328041077 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[9].display_name | Cancer research |
| concepts[10].id | https://openalex.org/C2779013556 |
| concepts[10].level | 3 |
| concepts[10].score | 0.45180854201316833 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q181876 |
| concepts[10].display_name | Metastasis |
| concepts[11].id | https://openalex.org/C126322002 |
| concepts[11].level | 1 |
| concepts[11].score | 0.3957071304321289 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[11].display_name | Internal medicine |
| concepts[12].id | https://openalex.org/C143998085 |
| concepts[12].level | 1 |
| concepts[12].score | 0.3738822937011719 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[12].display_name | Oncology |
| concepts[13].id | https://openalex.org/C121608353 |
| concepts[13].level | 2 |
| concepts[13].score | 0.26346004009246826 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[13].display_name | Cancer |
| concepts[14].id | https://openalex.org/C2776694085 |
| concepts[14].level | 2 |
| concepts[14].score | 0.24560078978538513 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q974135 |
| concepts[14].display_name | Chemotherapy |
| concepts[15].id | https://openalex.org/C2780030458 |
| concepts[15].level | 4 |
| concepts[15].score | 0.185691237449646 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q7041828 |
| concepts[15].display_name | Nivolumab |
| concepts[16].id | https://openalex.org/C2777701055 |
| concepts[16].level | 3 |
| concepts[16].score | 0.12480324506759644 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q1427096 |
| concepts[16].display_name | Immunotherapy |
| concepts[17].id | https://openalex.org/C2776232967 |
| concepts[17].level | 3 |
| concepts[17].score | 0.0 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q6743514 |
| concepts[17].display_name | Malignant pleural effusion |
| concepts[18].id | https://openalex.org/C2778239845 |
| concepts[18].level | 3 |
| concepts[18].score | 0.0 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q412415 |
| concepts[18].display_name | Cisplatin |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8374984264373779 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/crizotinib |
| keywords[1].score | 0.8286832571029663 |
| keywords[1].display_name | Crizotinib |
| keywords[2].id | https://openalex.org/keywords/anaplastic-lymphoma-kinase |
| keywords[2].score | 0.7643359899520874 |
| keywords[2].display_name | Anaplastic lymphoma kinase |
| keywords[3].id | https://openalex.org/keywords/alectinib |
| keywords[3].score | 0.702530026435852 |
| keywords[3].display_name | Alectinib |
| keywords[4].id | https://openalex.org/keywords/bevacizumab |
| keywords[4].score | 0.6311084032058716 |
| keywords[4].display_name | Bevacizumab |
| keywords[5].id | https://openalex.org/keywords/lung-cancer |
| keywords[5].score | 0.6037223935127258 |
| keywords[5].display_name | Lung cancer |
| keywords[6].id | https://openalex.org/keywords/carboplatin |
| keywords[6].score | 0.6015071272850037 |
| keywords[6].display_name | Carboplatin |
| keywords[7].id | https://openalex.org/keywords/atezolizumab |
| keywords[7].score | 0.5846185684204102 |
| keywords[7].display_name | Atezolizumab |
| keywords[8].id | https://openalex.org/keywords/adenocarcinoma |
| keywords[8].score | 0.5373453497886658 |
| keywords[8].display_name | Adenocarcinoma |
| keywords[9].id | https://openalex.org/keywords/cancer-research |
| keywords[9].score | 0.49228349328041077 |
| keywords[9].display_name | Cancer research |
| keywords[10].id | https://openalex.org/keywords/metastasis |
| keywords[10].score | 0.45180854201316833 |
| keywords[10].display_name | Metastasis |
| keywords[11].id | https://openalex.org/keywords/internal-medicine |
| keywords[11].score | 0.3957071304321289 |
| keywords[11].display_name | Internal medicine |
| keywords[12].id | https://openalex.org/keywords/oncology |
| keywords[12].score | 0.3738822937011719 |
| keywords[12].display_name | Oncology |
| keywords[13].id | https://openalex.org/keywords/cancer |
| keywords[13].score | 0.26346004009246826 |
| keywords[13].display_name | Cancer |
| keywords[14].id | https://openalex.org/keywords/chemotherapy |
| keywords[14].score | 0.24560078978538513 |
| keywords[14].display_name | Chemotherapy |
| keywords[15].id | https://openalex.org/keywords/nivolumab |
| keywords[15].score | 0.185691237449646 |
| keywords[15].display_name | Nivolumab |
| keywords[16].id | https://openalex.org/keywords/immunotherapy |
| keywords[16].score | 0.12480324506759644 |
| keywords[16].display_name | Immunotherapy |
| language | en |
| locations[0].id | doi:10.2147/ott.s404035 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S120324992 |
| locations[0].source.issn | 1178-6930 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1178-6930 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | OncoTargets and Therapy |
| locations[0].source.host_organization | https://openalex.org/P4310320348 |
| locations[0].source.host_organization_name | Dove Medical Press |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320348 |
| locations[0].source.host_organization_lineage_names | Dove Medical Press |
| locations[0].license | cc-by-nc |
| locations[0].pdf_url | https://www.dovepress.com/getfile.php?fileID=90671 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | OncoTargets and Therapy |
| locations[0].landing_page_url | https://doi.org/10.2147/ott.s404035 |
| locations[1].id | pmid:37384219 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | OncoTargets and therapy |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/37384219 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:10296560 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | cc-by-nc |
| locations[2].pdf_url | https://pmc.ncbi.nlm.nih.gov/articles/PMC10296560/pdf/ott-16-465.pdf |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | https://openalex.org/licenses/cc-by-nc |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Onco Targets Ther |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/10296560 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5021117068 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-3672-679X |
| authorships[0].author.display_name | Hirokazu Iso |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I80188885 |
| authorships[0].institutions[0].ror | https://ror.org/00krab219 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Nippon Medical School |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Hirokazu Iso |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[1].author.id | https://openalex.org/A5065516346 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-2026-9181 |
| authorships[1].author.display_name | Akihiko Miyanaga |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I80188885 |
| authorships[1].institutions[0].ror | https://ror.org/00krab219 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Nippon Medical School |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Akihiko Miyanaga |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[2].author.id | https://openalex.org/A5089485028 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Naohiro Kadoma |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I80188885 |
| authorships[2].institutions[0].ror | https://ror.org/00krab219 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Nippon Medical School |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Naohiro Kadoma |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[3].author.id | https://openalex.org/A5058702364 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Kaoruko Shinbu |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I80188885 |
| authorships[3].institutions[0].ror | https://ror.org/00krab219 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Nippon Medical School |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Kaoruko Shinbu |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[4].author.id | https://openalex.org/A5013701729 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-3774-8915 |
| authorships[4].author.display_name | Takehiro Tozuka |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I80188885 |
| authorships[4].institutions[0].ror | https://ror.org/00krab219 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Nippon Medical School |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Takehiro Tozuka |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[5].author.id | https://openalex.org/A5012788363 |
| authorships[5].author.orcid | |
| authorships[5].author.display_name | Akari Murata |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I80188885 |
| authorships[5].institutions[0].ror | https://ror.org/00krab219 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Nippon Medical School |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Akari Murata |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[6].author.id | https://openalex.org/A5028570171 |
| authorships[6].author.orcid | |
| authorships[6].author.display_name | Shunichi Nishima |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I80188885 |
| authorships[6].institutions[0].ror | https://ror.org/00krab219 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Nippon Medical School |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Shunichi Nishima |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[7].author.id | https://openalex.org/A5022308366 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-7605-8434 |
| authorships[7].author.display_name | Yozo Sato |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I80188885 |
| authorships[7].institutions[0].ror | https://ror.org/00krab219 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Nippon Medical School |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Yozo Sato |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[8].author.id | https://openalex.org/A5047912612 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-2298-6945 |
| authorships[8].author.display_name | Shinji Nakamichi |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I80188885 |
| authorships[8].institutions[0].ror | https://ror.org/00krab219 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Nippon Medical School |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Shinji Nakamichi |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[9].author.id | https://openalex.org/A5000338747 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-0246-395X |
| authorships[9].author.display_name | Masaru Matsumoto |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[9].institutions[0].id | https://openalex.org/I80188885 |
| authorships[9].institutions[0].ror | https://ror.org/00krab219 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Nippon Medical School |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Masaru Matsumoto |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[10].author.id | https://openalex.org/A5087922163 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-4912-4138 |
| authorships[10].author.display_name | Rintaro Noro |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[10].institutions[0].id | https://openalex.org/I80188885 |
| authorships[10].institutions[0].ror | https://ror.org/00krab219 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | Nippon Medical School |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Rintaro Noro |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[11].author.id | https://openalex.org/A5065103395 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-4495-7982 |
| authorships[11].author.display_name | Yasuhiro Terasaki |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan |
| authorships[11].institutions[0].id | https://openalex.org/I80188885 |
| authorships[11].institutions[0].ror | https://ror.org/00krab219 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | Nippon Medical School |
| authorships[11].author_position | middle |
| authorships[11].raw_author_name | Yasuhiro Terasaki |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Japan |
| authorships[12].author.id | https://openalex.org/A5100669294 |
| authorships[12].author.orcid | https://orcid.org/0000-0003-0367-2606 |
| authorships[12].author.display_name | Kaoru Kubota |
| authorships[12].countries | JP |
| authorships[12].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[12].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[12].institutions[0].id | https://openalex.org/I80188885 |
| authorships[12].institutions[0].ror | https://ror.org/00krab219 |
| authorships[12].institutions[0].type | education |
| authorships[12].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[12].institutions[0].country_code | JP |
| authorships[12].institutions[0].display_name | Nippon Medical School |
| authorships[12].author_position | middle |
| authorships[12].raw_author_name | Kaoru Kubota |
| authorships[12].is_corresponding | False |
| authorships[12].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[13].author.id | https://openalex.org/A5048704135 |
| authorships[13].author.orcid | https://orcid.org/0000-0002-1572-5472 |
| authorships[13].author.display_name | Masahiro Seike |
| authorships[13].countries | JP |
| authorships[13].affiliations[0].institution_ids | https://openalex.org/I80188885 |
| authorships[13].affiliations[0].raw_affiliation_string | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| authorships[13].institutions[0].id | https://openalex.org/I80188885 |
| authorships[13].institutions[0].ror | https://ror.org/00krab219 |
| authorships[13].institutions[0].type | education |
| authorships[13].institutions[0].lineage | https://openalex.org/I80188885 |
| authorships[13].institutions[0].country_code | JP |
| authorships[13].institutions[0].display_name | Nippon Medical School |
| authorships[13].author_position | last |
| authorships[13].raw_author_name | Masahiro Seike |
| authorships[13].is_corresponding | False |
| authorships[13].raw_affiliation_strings | Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.dovepress.com/getfile.php?fileID=90671 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2023-06-24T00:00:00 |
| display_name | Remarkable Clinical Response of ALK-Rearranged/TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report |
| has_fulltext | True |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10417 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9998999834060669 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2740 |
| primary_topic.subfield.display_name | Pulmonary and Respiratory Medicine |
| primary_topic.display_name | Lung Cancer Treatments and Mutations |
| related_works | https://openalex.org/W2556637976, https://openalex.org/W3159368590, https://openalex.org/W2767655639, https://openalex.org/W2753977688, https://openalex.org/W2940077771, https://openalex.org/W2917656567, https://openalex.org/W3158045290, https://openalex.org/W3194617801, https://openalex.org/W4388041986, https://openalex.org/W2969411178 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 3 |
| locations_count | 3 |
| best_oa_location.id | doi:10.2147/ott.s404035 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S120324992 |
| best_oa_location.source.issn | 1178-6930 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1178-6930 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | OncoTargets and Therapy |
| best_oa_location.source.host_organization | https://openalex.org/P4310320348 |
| best_oa_location.source.host_organization_name | Dove Medical Press |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320348 |
| best_oa_location.source.host_organization_lineage_names | Dove Medical Press |
| best_oa_location.license | cc-by-nc |
| best_oa_location.pdf_url | https://www.dovepress.com/getfile.php?fileID=90671 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by-nc |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | OncoTargets and Therapy |
| best_oa_location.landing_page_url | https://doi.org/10.2147/ott.s404035 |
| primary_location.id | doi:10.2147/ott.s404035 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S120324992 |
| primary_location.source.issn | 1178-6930 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1178-6930 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | OncoTargets and Therapy |
| primary_location.source.host_organization | https://openalex.org/P4310320348 |
| primary_location.source.host_organization_name | Dove Medical Press |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320348 |
| primary_location.source.host_organization_lineage_names | Dove Medical Press |
| primary_location.license | cc-by-nc |
| primary_location.pdf_url | https://www.dovepress.com/getfile.php?fileID=90671 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by-nc |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | OncoTargets and Therapy |
| primary_location.landing_page_url | https://doi.org/10.2147/ott.s404035 |
| publication_date | 2023-06-01 |
| publication_year | 2023 |
| referenced_works | https://openalex.org/W3155376330, https://openalex.org/W4252867417, https://openalex.org/W2999090889, https://openalex.org/W3015901031, https://openalex.org/W2805354595, https://openalex.org/W3181431627, https://openalex.org/W2012295597, https://openalex.org/W3129769609, https://openalex.org/W2482427906, https://openalex.org/W3173076954, https://openalex.org/W2785110924, https://openalex.org/W2035658420, https://openalex.org/W2889170871, https://openalex.org/W2588632379, https://openalex.org/W3111588936, https://openalex.org/W2936661866, https://openalex.org/W2561459036, https://openalex.org/W3171656849, https://openalex.org/W3128010851, https://openalex.org/W2791040477, https://openalex.org/W3084409519, https://openalex.org/W2062783581, https://openalex.org/W2169083371, https://openalex.org/W2156906256, https://openalex.org/W3003499321 |
| referenced_works_count | 25 |
| abstract_inverted_index.a | 12, 63, 144, 151 |
| abstract_inverted_index.We | 58 |
| abstract_inverted_index.in | 48 |
| abstract_inverted_index.is | 38, 161, 175 |
| abstract_inverted_index.of | 16, 18, 33, 44, 62, 85, 113, 125, 153, 163 |
| abstract_inverted_index.on | 41 |
| abstract_inverted_index.to | 56, 75, 132, 148, 177 |
| abstract_inverted_index.and | 96, 128, 134, 157 |
| abstract_inverted_index.are | 28, 54 |
| abstract_inverted_index.did | 119 |
| abstract_inverted_index.for | 11, 30, 167 |
| abstract_inverted_index.not | 107, 120 |
| abstract_inverted_index.one | 162 |
| abstract_inverted_index.p53 | 99 |
| abstract_inverted_index.the | 31, 42, 60, 86, 110, 116, 122, 135, 141, 164 |
| abstract_inverted_index.who | 71 |
| abstract_inverted_index.ABCP | 160 |
| abstract_inverted_index.case | 61 |
| abstract_inverted_index.cell | 20 |
| abstract_inverted_index.lung | 4, 21, 34, 51, 69, 169 |
| abstract_inverted_index.male | 65 |
| abstract_inverted_index.that | 53, 174 |
| abstract_inverted_index.were | 106 |
| abstract_inverted_index.with | 6, 50, 67, 82, 150, 171 |
| abstract_inverted_index.4-ALK | 93 |
| abstract_inverted_index.cases | 17 |
| abstract_inverted_index.liver | 8, 46, 77, 87, 117, 172 |
| abstract_inverted_index.rapid | 73 |
| abstract_inverted_index.serum | 123 |
| abstract_inverted_index.small | 14 |
| abstract_inverted_index.there | 37 |
| abstract_inverted_index.total | 126 |
| abstract_inverted_index.tumor | 97 |
| abstract_inverted_index.while | 79 |
| abstract_inverted_index.Biopsy | 84 |
| abstract_inverted_index.cancer | 52, 170 |
| abstract_inverted_index.fusion | 95 |
| abstract_inverted_index.kinase | 25 |
| abstract_inverted_index.levels | 124 |
| abstract_inverted_index.number | 15 |
| abstract_inverted_index.report | 59 |
| abstract_inverted_index.(ABCP). | 159 |
| abstract_inverted_index.Despite | 109 |
| abstract_inverted_index.Several | 23 |
| abstract_inverted_index.biliary | 129 |
| abstract_inverted_index.cancer. | 22, 35 |
| abstract_inverted_index.enzymes | 130 |
| abstract_inverted_index.general | 137 |
| abstract_inverted_index.limited | 39 |
| abstract_inverted_index.optimal | 165 |
| abstract_inverted_index.options | 166 |
| abstract_inverted_index.patient | 66, 142 |
| abstract_inverted_index.protein | 98 |
| abstract_inverted_index.ALK-TKIs | 178 |
| abstract_inverted_index.Finally, | 140 |
| abstract_inverted_index.However, | 36 |
| abstract_inverted_index.accounts | 10 |
| abstract_inverted_index.clinical | 146 |
| abstract_inverted_index.evidence | 40 |
| abstract_inverted_index.lymphoma | 1 |
| abstract_inverted_index.multiple | 7, 45, 76 |
| abstract_inverted_index.notably, | 102 |
| abstract_inverted_index.patients | 49 |
| abstract_inverted_index.respond, | 121 |
| abstract_inverted_index.response | 147 |
| abstract_inverted_index.revealed | 89 |
| abstract_inverted_index.therapy. | 179 |
| abstract_inverted_index.ALK-TKIs, | 115 |
| abstract_inverted_index.ALK-TKIs. | 57 |
| abstract_inverted_index.available | 29 |
| abstract_inverted_index.bilirubin | 127 |
| abstract_inverted_index.continued | 131 |
| abstract_inverted_index.detected. | 108 |
| abstract_inverted_index.exhibited | 143 |
| abstract_inverted_index.increase, | 133 |
| abstract_inverted_index.mutation; | 101 |
| abstract_inverted_index.mutations | 105 |
| abstract_inverted_index.non-small | 19 |
| abstract_inverted_index.patient's | 136 |
| abstract_inverted_index.receiving | 80 |
| abstract_inverted_index.secondary | 104 |
| abstract_inverted_index.treatment | 32, 43, 81, 149 |
| abstract_inverted_index.worsened. | 139 |
| abstract_inverted_index.(ALK-TKIs) | 27 |
| abstract_inverted_index.<i>ALK</i> | 103 |
| abstract_inverted_index.Anaplastic | 0 |
| abstract_inverted_index.alectinib. | 83 |
| abstract_inverted_index.appearance | 138 |
| abstract_inverted_index.echinoderm | 90 |
| abstract_inverted_index.inhibitors | 26 |
| abstract_inverted_index.metastases | 9, 47, 78, 88, 118 |
| abstract_inverted_index.metastasis | 173 |
| abstract_inverted_index.paclitaxel | 158 |
| abstract_inverted_index.refractory | 55, 176 |
| abstract_inverted_index.relatively | 13 |
| abstract_inverted_index.remarkable | 145 |
| abstract_inverted_index.sequential | 111 |
| abstract_inverted_index.42-year-old | 64 |
| abstract_inverted_index.combination | 152 |
| abstract_inverted_index.experienced | 72 |
| abstract_inverted_index.progression | 74 |
| abstract_inverted_index.ALK-positive | 68, 168 |
| abstract_inverted_index.ALK-tyrosine | 24 |
| abstract_inverted_index.bevacizumab, | 155 |
| abstract_inverted_index.carboplatin, | 156 |
| abstract_inverted_index.protein-like | 92 |
| abstract_inverted_index.(<i>TP53</i>) | 100 |
| abstract_inverted_index.atezolizumab, | 154 |
| abstract_inverted_index.(ALK-positive) | 3 |
| abstract_inverted_index.adenocarcinoma | 5, 70 |
| abstract_inverted_index.administration | 112 |
| abstract_inverted_index.kinase-positive | 2 |
| abstract_inverted_index.third-generation | 114 |
| abstract_inverted_index.(<i>EML4-ALK</i>) | 94 |
| abstract_inverted_index.microtubule-associated | 91 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 95 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 14 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8600000143051147 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.8366728 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |